DTaP-IPV-Hep B-Hib vaccine (Hexyon®/Hexacima®): A guide to its use in the primary and booster vaccination of infants and toddlers in Europe
Drugs and Therapy Perspectives, ISSN: 1172-0360, Vol: 29, Issue: 11, Page: 329-335
2013
- 13Citations
- 13Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Hexyon®/Hexacima® (DTaP-IPV-Hep B-Hib) is a new thiomersal-free hexavalent combination paediatric vaccine indicated for the primary and booster vaccination of infants and toddlers from 6 weeks to 24 months of age in Europe. Clinical data indicate that vaccination with this vaccine is a safe and immunogenic option for providing protection against the serious childhood infections of diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b. Its fully liquid ready-to-use formulation is convenient and simplifies administration by healthcare professionals. © 2013 Springer International Publishing Switzerland.
Bibliographic Details
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know